Outcome of Kidney Transplantation Using Organs from Executed Prisoners: Is It Justified Beyond the Ethical Issue?  by Shu, Kuo-Hsiung et al.
J Chin Med Assoc • May 2007 • Vol 70 • No 5 193
© 2007 Elsevier. All rights reserved.
Introduction
Kidney transplantation is the treatment of choice for
most patients with end-stage renal disease (ESRD).
However, organ shortage remains a serious problem
worldwide in meeting the ever-increasing demand for
organs. In Taiwan, renal transplantation has been a well-
established surgical procedure since 1968. However,
the transplant rate has been low in ESRD patients and
fewer than 200 cadaveric renal transplantations are per-
formed each year (Lee, Annual meeting of the Taiwan
Society of Nephrology, 2003), which represents < 3%
of the patients on the waiting list. Despite the enthu-
siastic promotion of living-related and living-unrelated
kidney transplantation via education and public media
advertisement, the transplantation rate is still low com-
pared to that of other developed countries.1 Owing
to these circumstances, many Taiwanese have sought
alternative ways to obtain organs; the most popular way
is to undergo kidney transplantation in Mainland China,
where using organs from executed prisoners is not
prohibited.2 From the standpoint of ethics, the use of
organs from executed prisoners should be condemned,
at least according to Western nations. However, contro-
versy has been raised3,4 and there is no easy answer to
this question. Moreover, few papers have addressed the
clinical aspects beyond the ethical issues5,6 and most
of the reports are either out of date or incomplete.
There is an urgent need for information concerning
organ transplantations in Mainland China using organs
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from executed prisoners. In this report, we present clin-
ical data based on our experience over the past 15 years
while avoiding the discussion of ethical issues.
Methods
Between January 1990 and September 2004, a total
of 435 kidney transplantations were performed in
Mainland China with post-transplant follow-up in our
hospital (group M). This was compared with kidney
transplants performed in our hospital during the same
period (group T, n = 200). Kidney transplants for pa-
tients in group M were performed at 26 different hospi-
tals around China but most of them were performed
in Canton Province, which is located in southern China
close to Hong Kong. Most of the patients in group M
returned to Taiwan within 1–4 weeks postoperatively
and were subsequently followed up by our faculty, who
also took care of patients in group T. The post-transplant
immunosuppressive regimens were similar in both
groups and were composed of triple therapy, including
corticosteroid, calcineurin inhibitor (cyclosporine or
tacrolimus) and anti-metabolite (azathioprine or my-
cophenolate mofetil [MMF]). After 1999, most of the
patients in both groups also received anti-CD25 induc-
tion therapy (baxillisimab 20 mg on day 0 and day 4
or daclizumab 50 mg on day 0 and day 14). Before
1994, human leukocyte antigen (HLA) tissue typing
was not performed routinely in group M patients, and
only incomplete data were subsequently obtained. Pre-
transplant evaluations were sometimes incomplete in
group M because many patients decided to undergo
transplantation without notifying us. In group T, tissue
typing as well as thorough evaluations were routinely
performed pre-transplant. The selection of recipients
in group T was mainly based on the extent of HLA
matching and other factors such as age, status of hepati-
tis virus infection and comorbidity. Acute rejection was
diagnosed based on clinical data and in most of the
cases further supported by a graft biopsy. Anti-rejection
therapy was begun with methylprednisolone pulse,
0.5 g intravenously for 3 consecutive days and if it
failed, was followed by anti-lymphocyte globulin at a
dose of 10 mg/kg/day or thymoglobulin at a dose of
1.5–2.5 mg/kg/day for 7–10 days.
Statistical analysis
Data were expressed as mean and standard deviation
unless otherwise specified. Continuous variables were
compared with a t test and frequencies compared with
a χ2 test. Patient and graft survival rates were calculated
with Kaplan–Meier method. To delineate change in
survival rate in different periods, we stratified the
patients further into 3 subgroups: T-1or M-1, T-2 or
M-2, and T-3 or M-3 for group T or M patients
whose transplantations were performed between
1990 and 1994, 1995 and 2000, and 2000 and 2004,
respectively. Comparisons of survival rates between
groups were performed with a log-rank test. A p value
< 0.05 was considered statistically significant.
Results
Table 1 depicts and compares demographic data of
groups M and T. Group M patients were older at
transplantation (45.0 ± 12.3 vs. 36.3 ± 10.8 years, 
p < 0.001) and had shorter duration of pre-transplant
dialysis (median: 13.2 vs. 29.4 months, p < 0.001).
The duration of follow-up was also shorter in group M
(6.2 ± 4.3 vs. 7.3 ± 4.6 years, p = 0.005). The prevalence
Table 1. Patient characteristics
Group T (n = 200) Group M (n = 435) p
Age at transplant (yr) 36.3 ± 10.8 45.0 ± 12.3 < 0.001
Sex (% male) 54.0 59.4 NS
DM (%) 3.0 7.3 NS
Hepatitis C (%) 18.3 10.2 0.02
Hepatitis B (%) 10.5 12.1 NS
Dialysis duration (mo)* 29.4 (0–183) 13.2 (0–162) < 0.001
Follow-up duration (yr) 7.3 ± 4.6 6.2 ± 4.3 0.005
HLA-AB mm 1.89 ± 0.89 NA
HLA-DR mm 0.79 ± 0.55 NA
Use FK (%) 22.2 37.0 0.001
Use MMF (%) 39.5 59.9 < 0.001
*Expressed as median and range. Data were compared by χ2 test. T = Taiwan; M = Mainland China; NS = not significant; DM = diabetes mellitus; mm =
mismatch; NA = not available; FK = FK506 (tacrolimus); MMF = mycophenolate mofetil.
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of pre-transplant hepatitis B virus (HBV) infection was
similar in both groups, but the prevalence of hepatitis
C virus (HCV) infection was significantly lower in
group M (10.2% vs. 18.3%, p=0.02). The mean number
of mismatches in group T was 2.1±0.8 for HLA-AB and
0.8 ± 0.6 for HLA-DR. More patients from group M
received tacrolimus and MMF. There was no significant
difference in the prevalence of pre-transplant diabetes
mellitus. Table 2 and Figure 1 show the comparison of
patient and graft survival rates between the 2 groups.
The 1-year, 5-year, and 10-year patient survival rates
were 94.3%, 89.5%, and 85.2%, respectively, for group
T and 92.6%, 85.4%, and 76.7%, respectively for
group M (p > 0.05), whereas the corresponding graft
survival rates were 91.4%, 82.6%, and 66.9%, respec-
tively for group T and 91.6%, 80.0%, and 61.4%, respec-
tively for group M (p > 0.05). Table 3, Figures 2 and 3
compare survival rates in subgroups of patients who
underwent transplantation in different periods. A sig-
nificantly better graft survival rate was found in patients
who underwent transplantation between 2000 and
2004 (subgroups T-3 and M-3). A significantly better
patient survival rate was also found in group M patients
who underwent transplantation in this period (M-3).
As a whole, group M patients showed a clear trend of
constantly improving patient and graft survival as time
went on. This trend was maintained until the end of
5th year post-transplant. Table 4 depicts the complica-
tions following renal transplantation. No significant
difference was found in terms of surgical complication,
post-transplant diabetes mellitus (PTDM) or malig-
nancy. A significantly lower acute rejection rate was
found in group M during the 1st year post-transplant
(24.5 vs. 31.1%, p = 0.015). Table 5 shows the causes of
Table 2. Comparison of patient and graft survival
Survival
Group T (n = 200) Group M (n = 435)
Patient (%) Graft (%) Patient (%) Graft (%)
1-yr 94.3 91.4 92.6 91.6
5-yr 89.5 82.6 83.6 80.0
10-yr 85.2 66.9 76.7 61.4
Data were analyzed with Kaplan–Meier method and compared with log-rank
test. No statistically significant difference was found between the 2 groups
in either patient or graft survival.
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Figure 1. Comparison of (A) patient survival and (B) graft survival rates between group T and group M. There was no statistically signifi-
cant difference.
Table 3. Survival analysis by 3 different periods according to time of transplantation
Time of TX
Group T (n = 200) Group M (n = 435)
Patient survival (%) Graft survival (%) Patient survival (%) Graft survival (%)
(period)
1-yr 5-yr 1-yr 5-yr 1-yr 5-yr 1-yr 5-yr
I 90.1 86.1 89.0 82.0 88.4 78.7 86.3 72.7
II 95.7 91.5 85.4 73.2 91.5 84.3 90.8 79.2
III 96.0 96.0 98.5 98.5
p NS 0.043 < 0.0001 0.0001
Survival analysis was performed by using Kaplan–Meier method. For comparison among subgroups transplanted in different periods, a log-rank test was used.
Period I = 1990–1994; period II = 1995–1999; period III = 2000–2004.
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patient mortality. A remarkable proportion of deaths
occurred outside our hospital and definite diagnoses
were not available. Since cardiovascular complications
are the leading cause of death in uremic patients and
may persist even after kidney transplantation,7 it was
assumed that most of these deaths were of cardiac ori-
gin. For the known causes, infection ranked first, fol-
lowed by malignancy and hepatic failure. For each cause
of death, there was no statistically significant difference
between groups T and M.
Discussion
The present study showed that kidney transplantations
performed in Mainland China using organs from exe-
cuted prisoners had results and complication rates com-
parable to those performed in Taiwan. To the best of our
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Figure 2. Comparison of (A) patient survival and (B) graft survival rates according to transplant year in group T. A significantly better
graft survival rate was found in the years 2000–2004 (group T-3). There was also a trend of better patient survival in group T-3,
although this was not statistically significant.
0 2 4 6 8 10 12 14 16
0.0
0.2
0.4
0.6
Pr
op
or
tio
n 
su
rv
iv
al
0.8
1.0
A
Group M-1
n = 165
Group M-2
n = 130
Group M-3
n = 140
Group M-1 vs. Group M-2, p = 0.056
Group M-1 vs. Group M-3, p < 0.0001
Group M-2 vs. Group M-3, p < 0.002
Year
B
Group M-1
Group M-2
Group M-3
Group M-1 vs. Group M-2, p = NS
Group M-1 vs. Group M-3, p < 0.0005
Group M-2 vs. Group M-3, p < 0.002
0 2 4 6 8
Year 
10 12 14 16
0.0
0.2
0.4
0.6
Pr
op
or
tio
n 
su
rv
iv
al
0.8
1.0
Figure 3. Comparison of (A) patient survival and (B) graft survival rates according to transplant year in group M. Both patient and graft
survival rates improved over time, and a significant improvement was noted in the years 2000–2004 (group M-3).
Table 4. Complications following renal transplantation*
Group T Group M p
(n = 200) (n = 435)
Surgical complication 6.5 5.6 NS
PTDM 8.0 12.9 NS
Malignancy 5.0 7.9 NS
First-year acute rejection 31.1 24.5 0.015
*Data are presented as % and compared by χ2 test. NS = not significant;
PTDM = post-transplant diabetes mellitus.
Table 5. Comparison of cause of death*
Group T Group M p
(n = 200) (n = 435)
Infection 9 (34.6) 36 (48.0) NS
Unknown 6 (23.1) 6 (8.0) NS
Malignancy 4 (15.4) 15 (20.0) NS
Hepatic failure 4 (15.4) 13 (17.3) NS
CVA 2 (7.7) 3 (4.0) NS
UGI bleeding 1 (3.9) 1 (1.3) NS
Acute pancreatitis 0 (0) 1 (1.3) NS
Total 26 75
*Data are presented as n (%) and compared by c2 test. NS = not significant;
CVA = cerebrovascular accident; UGI = upper gastrointestinal.
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knowledge, this is the largest series to date concerning
renal transplantation using organs from executed pris-
oners. The prevailing negative altitude toward the use
of organs from executed prisoners may account for
the rarity of such reports. Despite education and warn-
ing from physicians and public media about the risk
and ethical issues involved, uremic patients continue
to go to Mainland China for transplantation because of
the severe shortage of organs in Taiwan. According to
the USRDS annual report,1 Taiwan ranks first in the
incidence and second in the prevalence of ESRD in
the world. The waiting list for renal transplantation in
Taiwan is rapidly growing and now exceeds 6,700,
whereas the total number of cadaveric kidney trans-
plantations islandwide has remained relatively stable
at around 200 cases each year for many years. Hence,
academic and safety information concerning renal trans-
plantation in China, beyond the ethical issue, is urgently
needed.
The older age of group M patients simply reflects
the fact that aged uremic patients are less likely to be
selected for transplantation in Taiwan. The significantly
shorter duration of pre-transplant dialysis in group M
(median: 13.2 vs. 29.4 months; p < 0.001) was largely
due to a substantial proportion of recipients receiving
no dialysis at all before the surgery, i.e. preemptive
transplantation, which is impossible to be listed for
cadaveric renal transplantation in Taiwan. In group M,
most of the transplants performed before 1994 were
not matched for HLA tissue typing. Poor HLA-matched
kidney transplantation is supposedly associated with
increased susceptibility to acute rejection and inferior
graft survival.8 Also, older age was associated with
increased risk of graft failure according to a previous
report from the UK.9 Unexpectedly, our series showed
that group M had a significantly lower 1st-year acute
rejection rate (Table 4, 24.5% vs. 31.1%; p = 0.015). It
is possible that HLA matching might actually have
been performed after 1994 in some of the transplant
centers in Mainland China, although we were not
able to obtain the data. Moreover, a diminishing effect
of HLA matching on kidney survival has been demon-
strated in a recent study.10 Based on a large scale
cohort study of kidney transplants registered with
UNOS, the authors found that after 1998, only ‘6-
antigen mismatches’ significantly increased the hazard
of graft loss.10 Moreover, preemptive renal transplan-
tation has been noted to be associated with better
graft survival.11,12 In another study, a shorter duration
of pre-transplant dialysis was associated with better
patient and graft survival.13 These results may partly
explain why group M had a survival rate comparable
to that of group T (Table 2 and Figure 1). Furthermore,
based on personal preference, and probably other
unknown reasons, transplant physicians in Mainland
China tend to more frequently prescribe tacrolimus as
compared to cyclosporine and MMF as compared to
azathioprine (Table 1). Both drugs have been demon-
strated to be associated with a lower incidence of acute
rejection14,15 and thus may have further contributed
to a satisfactory graft and patient survival rate in
group M. The analysis of survival data stratified by 3
different periods when kidney transplantations were
performed further supports the assumption (Table 3,
Figures 2 and 3). Although all the patients in group T
were HLA-matched as well as possible, a significantly
better graft survival rate was obtained in subgroup T-3,
whose transplantations were performed between 2000
and 2004 as compared to patients who received trans-
plantations in the earlier periods (Figure 2). In our hos-
pital, the years when newer agents were introduced for
clinical transplantation were: tacrolimus 1997, MMF
1998 and anti-CD25 1999. The routine use of anti-
CD25 and the increase in the number of transplant
patients immunosuppressed with tacrolimus and MMF
after 1999 in both groups T and M resulted in a
remarkable reduction in the acute rejection rate in our
study. We speculate that this is the major reason why
the graft survival rate improved after 2000 in both
groups (T-3 and M-3). A recent US study also reported
a steady improvement in patient and graft survival rates
over the past 9 years (1988–1996).16
Previous studies5 have addressed the issue of hepa-
titis infection acquired during transplantation in
Mainland China, which constituted a major cause of
death among this population. Our series did not show
a similar finding, although a substantial proportion of
patients were infected with either HBV or HCV before
going to Mainland China for transplantation (Table 1).
Taiwan used to be an endemic area for HBV infection.
A survey performed in 1980 showed that over 90% of
the general population under the age of 40 has been
infected by HBV and 15–20% of these were chronic
carriers, while the HBV-naïve population was < 10%.17
The prevalence of HBV infection in our patients was
10.5% in group T and 12.1% in group M (Table 1).
These figures were very close to those obtained in
1981.17 With the launch of a nationwide vaccination
program since 1984, the prevalence of HBV infection
has been diminishing.18,19 In a recent survey, seropos-
itivity for anti-HBc, which represents the prevalence
of HBV infection, was found in 2.9% of persons < 15
years of age and in 20.6% of persons aged 15–20 years.
In the same age groups, the rates of anti-HBs seropos-
itivity were 75.8% and 70.7%, respectively.18 Based on
these figures and the mean age at transplantation in our
J Chin Med Assoc • May 2007 • Vol 70 • No 5198
K.H. Shu, et al
patients being 36.3 and 45.0 years in group T and
group M, respectively, we assumed that the HBV-naïve
population in our series was below 10%. Because it is
this subpopulation that is most vulnerable to HBV in-
fection, it may explain why HBV infection acquired in
Mainland China during transplantation was not a serious
complication in our series. Furthermore, based on our
previous successful experience with the treatment of
fulminating hepatitis B with lamivudine,20 we routinely
gave lamivudine to HBV-positive recipients as a pre-
emptive therapy for at least 2 years post-transplant. As
for active HCV infection, an ultralow dose interferon-α
and ribavirin were given for at least 1 year in a few
patients with reasonably good results and safety pro-
file.21 This management might have partly ameliorated
the impact of viral hepatitis on the patient and graft
survival. In fact, there was no statistically significant
difference in the percentage of mortality due to hepatic
failure between groups T and M (Table 5).
Malignancy is a major complication following renal
transplantation and the incidence was 6.2% in our pre-
vious report.22 In the present study, group M patients
had a higher incidence of malignancy compared to
group T patients, although it did not reach statistical
significance (Table 4, 7.9% vs. 5.0%, p > 0.05). Because
group M had a shorter duration of follow-up (Table 1),
it remains to be seen if a longer term of follow-up
would result in a significant higher incidence of malig-
nancy in this group.
While this study revealed an outcome of renal
transplantation comparable to that in Taiwan, caution
should be taken in the interpretation of the data.
Group M enrolled only patients who came back from
China, usually with functioning grafts. Hence, mortal-
ity that occurred shortly after transplantation was not
counted. Additionally, patients with primary nonfunc-
tion post-transplantation did not always return to our
hospital and were most likely followed up by the pri-
mary care nephrologists who also administered their
dialysis therapy. Therefore, these patients were not
counted in the present study. Taking these factors into
account, the present report may have overestimated
the survival rates in group M.
Finally and most importantly, the good transplan-
tation results using organs from executed prisoners
should not be used to justify this kind of surgery.
Currently, our policy is to discourage ESRD patients
from undergoing kidney transplantations in Mainland
China. However, these patients are usually determined
to undergo such transplantations and consequently
do not notify us until they come back from China.
In conclusion, we have shown that renal trans-
plantation using organs from executed prisoners had a
reasonably good outcome when compared with trans-
plantations in Taiwan. The outcome has been even
better in the past 5 years, which may reflect the devel-
opment of new transplantation medicine and better
care of the recipients. While the ethical issue remains
a major concern, quality care of these recipients should
not be abandoned and clearly, a more precise analysis
including early failures should be carried out in the
future.
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